Gastric Cancer Clinical Trials in Boston, Massachusetts
23 recruitingBoston, Massachusetts
Showing 1–20 of 23 trials
Recruiting
Phase 1
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Gastric CancerAdvanced Solid TumorNon-small Cell Lung Cancer+4 more
AstraZeneca70 enrolled15 locationsNCT06147037
Recruiting
Phase 3
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Esophageal CancerGastric Cancer (GC)Gastroesophageal Junction
SOFIE200 enrolled10 locationsNCT07217704
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Esophageal CancerGastric CancerCervical Cancer+5 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Esophageal CancerGastric CancerGastroesophageal Junction Adenocarcinoma
AstraZeneca2,130 enrolled258 locationsNCT07431281
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled286 locationsNCT06764875
Recruiting
Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871
Recruiting
Phase 3
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+12 more
Alliance for Clinical Trials in Oncology382 enrolled791 locationsNCT05677490
Recruiting
Phase 1
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+7 more
SystImmune Inc.280 enrolled17 locationsNCT06293898
Recruiting
Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Gastric CancerOvarian CancerEndometrial Cancer+1 more
AstraZeneca454 enrolled95 locationsNCT05489211
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Not Applicable
Resilience and Equity in Aging, Cancer, and Health (REACH)
Esophageal CancerPancreatic CancerGastric Cancer+3 more
Dana-Farber Cancer Institute257 enrolled1 locationNCT04674267
Recruiting
Phase 1
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Gastric CancerEsophageal AdenocarcinomaMetastatic Cancer+5 more
I-Mab Biopharma US Limited330 enrolled21 locationsNCT04900818
Recruiting
Phase 2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Gastric Cancer
AstraZeneca450 enrolled100 locationsNCT04379596
Recruiting
Not Applicable
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Gastric CancerInvasive Breast Cancer
Brigham and Women's Hospital70 enrolled2 locationsNCT04368702
Recruiting
Phase 1
IKS014 in Advanced Solid Tumors That Express HER2
Breast CancerGastric CancerGastroesophageal-junction Cancer
Iksuda Therapeutics Ltd.165 enrolled12 locationsNCT05872295
Recruiting
Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
HER2-positive Breast CancerHER2-positive Colorectal CancerHER2-positive Gastric Cancer+2 more
Mersana Therapeutics162 enrolled14 locationsNCT05514717
Recruiting
Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Pancreatic CancerGastric CancerLung Cancer+15 more
Apollomics Inc.497 enrolled35 locationsNCT03175224
Recruiting
Phase 1Phase 2
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+4 more
ModeX Therapeutics, An OPKO Health Company115 enrolled6 locationsNCT06239194
Recruiting
Not Applicable
Comprehensive Outcomes for After Cancer Health
Breast CancerMetastatic Breast CancerGastric Cancer+8 more
Pack Health625 enrolled7 locationsNCT05349227
Recruiting
Phase 1Phase 2
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer
Gastric Cancer
Idience Co., Ltd.100 enrolled14 locationsNCT04725994